"id","rationale","description","name","uuid:ID","label"
"StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","Study Design 1","8070824d-fe29-44f8-bd12-df97116ce7d5",""
